Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease : EMINENT-CD
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Patients with CD
• ≥ 18 to ≤ 75 years-old
• Symptomatic CD according to PRO-2 (stool \> 3 or abdominal pain score \> 1)
• Transmural inflammation on baseline MRI (C-score \> 0.5 in at least one segment)
Locations
Other Locations
France
CHU de Brest - Hôpital de la Cavale Blanche
NOT_YET_RECRUITING
Brest
CHU de Clermont Ferrand - Hôpital d'Estaing
RECRUITING
Clermont-ferrand
CHU de Nîmes Carémeau
NOT_YET_RECRUITING
Nîmes
Institut Mutualiste Monsouris
NOT_YET_RECRUITING
Paris
CHU de Toulouse - Hôpital Rangueil
NOT_YET_RECRUITING
Toulouse
CH de Valence
NOT_YET_RECRUITING
Valence
Contact Information
Primary
Julie MUSSOT
jmussot@getaid.org
+33 6 27 49 29 10
Backup
Noemie DA COSTA
ndacosta@getaid.org
+33 9 72 57 61 60
Time Frame
Start Date: 2026-05-11
Estimated Completion Date: 2028-11
Participants
Target number of participants: 75
Treatments
Experimental: Mirikizumab treatment
Mirikizumab will be used as scheduled in the drug label: induction with IV infusions (900 mg) at week 0, week 4 and week 8.~For clinical responders: SC injections (300 mg) at W12 and every 4 weeks For clinical non-responders: SC injections (300 mg) at W12 and every 4 weeks
Related Therapeutic Areas
Sponsors
Leads: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives